ArticleJournal of translational medicine2026
SP-printer: reconstruction of tumor stage-specific microenvironments via phenotype-integrated spatial transcriptomics.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSpatial transcriptomics (ST) technologies have rapidly advanced the investigation of tumor microenvironment (TME) mechanisms by enabling high-resolution mapping of mRNA molecules within their native spatial context. However, existing methods often overlook phenotypic indices like malignancy status, limiting their interpretability within the tumor microenvironment.
methodsThis work proposes SP-printer (Spatial-Phenotype printer), a flexible integrating approach that integrates phenotypic and spatial data to quantify stage-specific malignancy levels at each spot. SP-printer first identifies stage-specific metagenes from bulk RNA-seq datasets by using a S-score strategy. These metagenes are then projected onto ST data at pixel level via an information-enhanced mapping strategy, generating spatially resolved stage phenotypes. Finally, the pixel-level mappings are aggregated to spot resolution, enabling compatibility with standard ST workflows and supporting downstream analyses.
resultsSP-printer outperforms state-of-the-art methods in identifying malignant regions across diverse tumor tissues. Specifically, we identified early microenvironment diagnostic markers for primary liver cancer and liver metastasis and evaluated the effects of seven drugs on the tumor microenvironment, providing a comprehensive assessment of their therapeutic potential.
conclusionsSP-printer offers a unified framework to dissect the tumor spatial microenvironment and bridge the gap between cellular context and phenotypic outcomes, thereby enhancing the precision of tumor microenvironment analysis and facilitating informed clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.